Protagonist Therapeutics (PTGX) Current Assets (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Current Assets data on file, last reported at $613.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 1.25% year-over-year to $613.5 million; the trailing twelve-month figure through Mar 2026 stood at $613.5 million (up 1.25% YoY), and the FY2025 full-year result was $577.6 million, down 2.38% from the prior year.
• Current Assets grew to $613.5 million in Q1 2026, from $577.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $627.6 million in Q1 2024 to a low of $235.7 million in Q1 2023.
• A 5-year average of $450.1 million and a median of $476.8 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets sank 30.97% in 2023 and soared 166.21% in 2024, its largest moves.
• Tracing PTGX's Current Assets over 5 years: stood at $243.1 million in 2022, then jumped by 46.28% to $355.6 million in 2023, then surged by 66.39% to $591.6 million in 2024, then decreased by 2.38% to $577.6 million in 2025, then advanced by 6.21% to $613.5 million in 2026.
• Business Quant data shows PTGX's Current Assets at $613.5 million in Q1 2026, $577.6 million in Q4 2025, and $586.4 million in Q3 2025.